Cite
HARVARD Citation
Pack, C. et al. (2020). Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer. Human vaccines & immunotherapeutics. 16 (12), pp. 3184-3193. [Online].